This is the text extract for Release of 2011/12 Invitation to Tender; Contact: Marcus Kim, browse documents here.

---

2 November 2011

Release of the 2011/12 Invitation to Tender

The 2011/12 Invitation to Tender (2011/12 ITT) has been approved by the PHARMAC Board and has been distributed today via the electronic tender (eTender) system. If you do not receive an e-mail containing the link to the eTender system and you would like to participate in this years tender, please contact Marcus Kim at marcus.kim@pharmac.govt.nz or on (04) 916 7263 so that your details can be added to our system. If you have already registered your e-mail address with us but you have not received an e-mail link we suggest that you check your e-mail spam filters (in case it has been caught by your filters) prior to contacting us. A complete copy of the 2011/12 ITT is also available on our website at the following link http://pharmac.govt.nz/suppliers/proposals/tenders. We will not be posting out any hard copies of the 2011/12 ITT. Changes to the 2011/12 ITT product list Please note that the product list (Schedule 2) consulted on in July 2011 has changed. Some products have been added, removed or amended either as a result of:     clinical advice received (i.e. from the Tender Medical Evaluation Subcommittee of PTAC and/or members of the Hospital Pharmaceuticals Subcommittee); and/or consultation responses received from suppliers, DHBs and/or medical groups; and/or a review of unresolved bids from previous tenders; and/or Alternative Commercial Proposals accepted by PHARMAC.

The following items have been added to the 2011/12 ITT:

Chemical Name Acetylcysteine Alprostadil Baclofen Baclofen Cefepime Hydrochloride Cefepime Hydrochloride Diltiazem Hydrochloride Domperidone Doxorubicin Fludarabine Phosphate Goserelin Acetate Granisetron Granisetron Oxycodone Hydrochloride Inj 200 mg per ml, 10 ml Inj 0.5 mg per ml, 1 ml Inj 0.05 mg per ml Oral liq 1 mg per ml Inj 1 g Inj 2 g Inj 5 mg per ml, 5 ml Tab 10 mg Powder for inj, 50 mg Tab 10 mg Inj 10.8 mg Inj 1 mg Tab 2 mg Inj 50 mg per ml Line Item

A462589 - qA21977 Page 1 of 5

---

Chemical Name Quinapril Quinapril Quinapril Quinapril with Hydrochlorothiazide Quinapril with Hydrochlorothiazide Sulindac Sulindac Tropisetron Tab 10 mg Tab 5 mg Tab 20 mg

Line Item

Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Tab 200 mg Tab 100 mg Inj 1 mg per ml, 5 ml

The following items that were included in consultation have been removed from the 2011/12 ITT:

Chemical Name Bimatoprost Calcipotriol Calcipotriol Calcipotriol Calcipotriol Calcipotriol Calcipotriol Capecitabine (current access) Capecitabine (current access) Capecitabine (widened access) Capecitabine (widened access) Donepezil hydrochloride Donepezil hydrochloride Doxepin hydrochloride Efavirenz Efavirenz Efavirenz Efavirenz Efavirenz Efavirenz Granisetron Mycophenolate Mofetil Mycophenolate Mofetil Mycophenolate Mofetil Mycophenolate Mofetil Line Item Eye Drops 0.03% Crm 50 mcg per g (pack size 30 g or less) Crm 50 mcg per g (pack size greater than 30 g) Oint 50 mcg per g (pack size 30 g or less) Oint 50 mcg per g (pack size greater than 30 g) Soln 50 mcg per ml (pack size 30 ml or less) Soln 50 mcg per ml (pack size greater than 30 ml) Tab 150 mg Tab 500 mg Tab 150 mg Tab 500 mg Tab 5 mg Tab 10 mg Tab 75 mg Cap 100 mg Cap 50 mg Tab 50 mg Tab 200 mg Tab 600 mg Cap 200 mg Transdermal patch 3.2 mg per 24 hours Tab 500 mg Inj 500 mg Powder for oral liq 1 g per 5 ml Cap 250 mg

The following items have been amended in the 2011/12 ITT:   Ritonavir has been amended from cap 100 mg to tab 100 mg. Methadone hydrochloride has been amended from oral liq 2 mg per ml to oral liq 1 mg 2 mg per ml.

A462589

Page 2 of 5

---

Summary of other changes to the 2011/12 ITT Additional Supply Pharmaceuticals (ASPs) ASPs have been added to the 2011/12 ITT as discussed during our July 2011 consultation letter. Suppliers bidding for line items that are designated ASPs will need to ensure that a minimum four months stock is held at all times. Clause 1.1 (b) of Schedule 5 Clause 1.1 (b) of Schedule 5 has been amended as discussed in our July 2011 consultation letter. Special Authority Criteria Some products have been tendered for both current access and widened access as discussed in our July 2011 consultation letter. Interest rate Clause 5.5 (a) of Schedule 5 and clause 7.5 (a) of Schedule 6 have been amended as follows (changes in bold and strikethrough):

(a) interest will accrue in such sum as remains unpaid at a rate per annum equal to the business base rate of ASB Bank Limited the relevant SME overdraft rate (weighted average rate) of the Reserve Bank of New Zealand plus five percentage points, calculated and compounded on a daily basis, from the due date until such time as the sum due (including interest) is paid in full. This obligation to pay default interest is to arise without the need for a notice or demand from PHARMAC for such default interest; and

We note that the above change was not consulted upon, as it arose after consultation had been distributed, and we considered consultation to be unnecessary. The reason for this change is to ensure that the rate used to calculate default interest is easily accessible online in a historical series, which the Reserve Bank of New Zealand (RBNZ) SME overdraft rate is. The actual impact on suppliers would be negligible as the SME overdraft rate is very similar to (and currently slightly below) the ASB business base rate. The RBNZ rate can be found at: http://www.rbnz.govt.nz/statistics/exandint/b3/data.html Evidence of market approval We no longer require suppliers to include evidence of market approval (i.e. the Medsafe TPDR) with their bids, as in most cases we have access to this information online through Medsafe’s website. Where a product does not have market approval, we continue to expect suppliers to provide an indication of the likely time required for products to gain approval from Medsafe (including the timing of dossier submission and whether dossiers are likely to be submitted under the abbreviated process).

A462589

Page 3 of 5

---

Data estimates provided during consultation on the 2011/12 ITT The following annual usage data was provided following requests from suppliers during the consultation period. These volumes are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any tender item. In order to be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2011/12 ITT remains open. Irinotecan:

Units FYR 2009 2010 2011 Inj 20 mg per ml, 5 ml - PCT 4,208 5,721 6,818 Inj 20 mg per ml, 2 ml - PCT 2,832 4,378 5,101

Carboplatin, doxorubicin, epirubicin, oxaliplatin, vinorelbine

Chemical Carboplatin Formulation Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 15 ml Inj 10 mg per ml, 45 ml Inj 10 mg Doxorubicin Inj 50 mg Inj 100 mg Inj 2 mg per ml, 5 ml Epirubicin Inj 2 mg per ml, 25 ml Inj 2 mg per ml, 50 ml Oxaliplatin Vinorelbine Inj 50 mg Inj 100 mg Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 5 ml Annual Units 27 12,424 1,755 6 8,007 944 78 4,638 393 1,655 7,074 5,045 665

Estimates of DHB hospital usage of various products:

Line Item Atracurium besylate inj 10 mg per ml, 2.5 ml Atracurium besylate inj 10 mg per ml, 5 ml Atropine sulphate inj 600 mcg per ml, 1 ml Clonidine inj 150 mcg per ml, 1 ml Fluconazole inj 2 mg per ml, 50 ml Annual DHB hospital usage 27,000 20,000 110,000 17,000 7,000

A462589

Page 4 of 5

---

Line Item Gentamicin sulphate inj 40 mg per ml, 2 ml Glyceryl trinitrate inj 1 mg per ml, 5 ml Glyceryl trinitrate inj 1 mg per ml, 50 ml Glyceryl trinitrate inj 5 mg per ml, 10 ml Methylprednisone acetate inj 40 mg per ml, 1 ml Methylprednisone sodium succinate inj 40 mg per ml, 1 ml Methylprednisone sodium succinate inj 62.5 mg per ml, 2 ml Methylprednisone sodium succinate inj 500 mg Methylprednisone sodium succinate inj 1 g Ondansetron inj 2 mg per ml, 2 ml Ondansetron inj 2 mg per ml, 4 ml Oxytocin inj 5 iu per ml, 1 ml Oxytocin inj 10 iu per ml, 1 ml Oxytocin inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Pancuronium bromide inj 2 mg per ml, 2 ml Rocuronium bromide inj 10 mg per ml, 5 ml Tranexamic acid inj 100 mg per ml, 5 ml

Annual DHB hospital usage 200,000 13,000 4,500 4,900 6,600 3,400 2,000 2,000 3,700 180,000 40,000 20,000 130,000 18,000 19,000 60,000 32,000

More information If you have any queries regarding the tender or require any assistance with the system please contact Marcus Kim at marcus.kim@pharmac.govt.nz or on (04) 916 7263.

A462589

Page 5 of 5